** Shares of drugmaker Atara Biotherapeutics fall 47.8% to $6.87 premarket
** U.S. FDA has declined to approve company's cancer therapy tabelecleucel
** FDA's decision was based on observations made during an inspection of a third-party manufacturing facility for the therapy - company
** If ATRA does not secure enough funding by Q1 2025, it intends to suspend all of CAR-T cell therapy programs and significantly reduce expenses and activities to only those that support tabelecleucel's approval
** Shares rose 3.8% in 2024
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。